0.33
4.30%
0.0136
Virpax Pharmaceuticals Inc Borsa (VRPX) Ultime notizie
Virpax Pharmaceuticals names new board director - Investing.com
Virpax Pharmaceuticals names new board director By Investing.com - Investing.com UK
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update - Defense World
Virpax Pharmaceuticals announces board member resignation By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals announces board member resignation - Investing.com
Virpax Pharmaceuticals stock hits 52-week low at $0.36 By Investing.com - Investing.com Canada
Virpax Pharmaceuticals stock hits 52-week low at $0.36 - Investing.com
Virpax Pharmaceuticals Extends Collaboration with NIH Center for Pain Management Innovation - MSN
VRPX (Virpax Pharmaceuticals) Enterprise Value : $3.71 Mil (As of Dec. 01, 2024) - GuruFocus.com
Virpax Pharmaceuticals lowers quorum requirement By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals lowers quorum requirement - Investing.com India
Virpax Pharmaceuticals : Amendments to Bylaws Form 8 K - Marketscreener.com
Virpax Pharmaceuticals Announces Positive Results in Study for Long-Lasting Pain Relief Formulation - MSN
Virpax Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Nigeria
Virpax Pharmaceuticals regains Nasdaq compliance - Investing.com India
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Virpax Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements and Makes Key Appointments - Defense World
Virpax Pharmaceuticals Strengthens Leadership and Expands Collaborations - TipRanks
Maxim Group Downgrades Virpax Pharmaceuticals (VRPX) - MSN
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur - Marketscreener.com
Why Is Virpax Pharmaceuticals Stock Gaining On Friday? - Benzinga
Virpax Pharmaceuticals extends NIH pain management research By Investing.com - Investing.com Australia
Virpax Pharma Gets Government Cooperation Deal Extension - Marketscreener.com
Virpax Pharmaceuticals extends NIH pain management research - Investing.com India
Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative - The Bakersfield Californian
Virpax Extends NIH Partnership for Novel Non-Addictive Pain Treatment Technology | VRPX Stock News - StockTitan
VRPX (Virpax Pharmaceuticals) Debt-to-EBITDA : 0.00 (As of Sep. 2024) - GuruFocus.com
Virpax Pharmaceuticals appoints new CFO - Investing.com
Virpax Pharmaceuticals appoints new CFO By Investing.com - Investing.com Canada
Virpax Pharmaceuticals Announces New Chief Financial Officer - TipRanks
Virpax Pharmaceuticals, Inc. Appoints Usama Chaudhry as Chief Financial Officer - Marketscreener.com
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering - The Manila Times
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Virpax Pharmaceuticals Raises $5M to Advance Pain Management Drug Development | VRPX Stock News - StockTitan
Virpax Pharmaceuticals Inc. (VRPX) Quarterly 10-Q Report - Quartzy
Virpax Pharmaceuticals Prices of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants - citybiz
Virpax Pharmaceuticals prices $5 million stock offering - Investing.com
Virpax Pharmaceuticals prices $5 million stock offering By Investing.com - Investing.com UK
Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug | VRPX Stock News - StockTitan
Adial Pharma Taps Veteran CFO with $150M+ Fundraising Track Record - StockTitan
Closing Bell Recap: Virpax Pharmaceuticals Inc (VRPX) Ends at 0.48, Reflecting a 1.06 Upturn - The Dwinnex
Virpax Pharmaceuticals Inc: Navigating a Turbulent Year, Up -95.58% from 52-Week Low - The InvestChronicle
VRPX stock touches 52-week low at $0.46 amid market challenges - Investing.com India
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):